We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STERIS: Synergy Health Deal to Drive Growth, Competition Rife
Read MoreHide Full Article
On Jun 28, we issued an updated research report on Ohio-based STERIS plc (STE - Free Report) , manufacturer and marketer of infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services. The company currently carries a Zacks Rank #3 (Hold).
STERIS acquired Synergy Health plc last year. The mega buyout has proven to be a success for its legacy business. The transaction created a new global leader in infection prevention and sterilization, which will offer improved healthcare services to medical device companies, pharma companies, hospitals and other healthcare facilities across the globe.
Going ahead, management expects Synergy acquisition to contribute $640–$650 million in revenues, which translates into low-single-digit growth, to the company’s operations in fiscal 2017. Management also provided a strong guidance for the overall business in 2017.
The bulk of STERIS’ revenues are generated in the healthcare and pharmaceutical markets, where growth is primarily driven by the aging global population. With life expectancy on the rise, a larger aging population increases the demand for medical procedures. This, in turn, drives the consumption of single-use medical devices and surgical kits processed by STERIS’ Isomedix segment.
Given the continued success of the company’s varied medical equipment, we believe that STERIS holds significant potential to expand its foothold in these markets.
On the flip side, the company expects to competition to continue, going ahead, due to the entry of new infection prevention, sterile processing, contamination control, gastrointestinal and surgical support products and services in the market. Moreover, currency headwinds have been hampering STERIS’ overseas growth for quite some time now, a trend which will likely continue.
Customer consolidation is a major concern for STERIS as well, partly due to healthcare cost reduction measures initiated to combat competitive pressures, along with legislators, regulators and third-party payors. Besides lingering macroeconomic softness like the ongoing turmoil in the Middle East, due to fluctuating oil prices, could hurt growth significantly.
Stocks to Consider
Some better-ranked medical stocks are Boston Scientific Corporation (BSX - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
STERIS: Synergy Health Deal to Drive Growth, Competition Rife
On Jun 28, we issued an updated research report on Ohio-based STERIS plc (STE - Free Report) , manufacturer and marketer of infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services. The company currently carries a Zacks Rank #3 (Hold).
STERIS acquired Synergy Health plc last year. The mega buyout has proven to be a success for its legacy business. The transaction created a new global leader in infection prevention and sterilization, which will offer improved healthcare services to medical device companies, pharma companies, hospitals and other healthcare facilities across the globe.
Going ahead, management expects Synergy acquisition to contribute $640–$650 million in revenues, which translates into low-single-digit growth, to the company’s operations in fiscal 2017. Management also provided a strong guidance for the overall business in 2017.
The bulk of STERIS’ revenues are generated in the healthcare and pharmaceutical markets, where growth is primarily driven by the aging global population. With life expectancy on the rise, a larger aging population increases the demand for medical procedures. This, in turn, drives the consumption of single-use medical devices and surgical kits processed by STERIS’ Isomedix segment.
Given the continued success of the company’s varied medical equipment, we believe that STERIS holds significant potential to expand its foothold in these markets.
On the flip side, the company expects to competition to continue, going ahead, due to the entry of new infection prevention, sterile processing, contamination control, gastrointestinal and surgical support products and services in the market. Moreover, currency headwinds have been hampering STERIS’ overseas growth for quite some time now, a trend which will likely continue.
Customer consolidation is a major concern for STERIS as well, partly due to healthcare cost reduction measures initiated to combat competitive pressures, along with legislators, regulators and third-party payors. Besides lingering macroeconomic softness like the ongoing turmoil in the Middle East, due to fluctuating oil prices, could hurt growth significantly.
Stocks to Consider
Some better-ranked medical stocks are Boston Scientific Corporation (BSX - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>